Pembrolizumab receives the green light from NICE for NSCLC subtype

Pembrolizumab (Keytruda®) is to be made available as a treatment option, in combination with chemotherapy, for the first-line treatment of adults with untreated metastatic squamous non-small cell lung cancer (NSCLC) via the Cancer Drugs Fund following a recommendation from NICE.The decision to recommend pembrolizumab makes it the first immunotherapy to be used in the first-line setting for metastatic squamous NSCLC regardless of PD-L1 expression, when combined with chemotherapy. “Pembrolizumab combination therapy is a promising treatment option for these patients who currently have very few. We are therefore pleased to be able to use the flexibility provided by the Cancer Drugs...